Researchers from the Kennedy Krieger Institute and four collaborating institutions have identified an unexpected biological pathway that may contribute to glaucoma.

Researchers at Boston University School of Medicine found little difference in the efficacy of the treatments Bevacizumab (Avastin) and Ranibizumab (Lucentis), used to treat age-related macular degeneration (AMD).